Abstract Number: Esoc2026a1846 Tailored Antiplatelet Secondary Prevention in Non-Cardioembolic Ischemic Stroke: A Phase Iv Gender-Stratified Randomized Controlled Trial (Tailor Trial) – Study Design
Why the study?
Many patients have biological non-responsiveness to antiplatelet agents, increasing early recurrence risk, but whether a tailored, platelet function-guided strategy improves short-term outcomes versus usual care in non-cardioembolic ischaemic stroke is unknown.
Does a tailored, platelet function-guided antiplatelet strategy reduce the composite of recurrent ischaemic stroke, myocardial infarction, or cardiovascular death in patients with recent non-cardioembolic ischaemic stroke compared to usual care?
Population
Patients with recent non-cardioembolic ischaemic stroke requiring secondary antiplatelet prevention across three Italian stroke centres
Comparison
Tailored platelet function-guided antiplatelet strategy vs usual care
Design
Phase IV multicentre pragmatic open-label gender-stratified RCT with blinded endpoint adjudication
Follow-up
3 months
Key result
The TAILOR trial is a planned randomized study designed to evaluate whether a platelet function-guided antiplatelet strategy reduces 3-month cardiovascular events from an assumed 9% to 5%.
Authors
Loading...
The TAILOR trial is designed to determine if a precision-medicine approach using platelet function testing to guide antiplatelet therapy reduces early cardiovascular events after non-cardioembolic ischemic stroke.
RCT
Open-label
1:1
Yes
Does a tailored, platelet function-guided antiplatelet strategy reduce the composite of recurrent ischaemic stroke, myocardial infarction, or cardiovascular death in patients with recent non-cardioembolic ischaemic stroke compared to usual care?
The TAILOR trial is designed to determine if a precision-medicine approach using platelet function testing to guide antiplatelet therapy reduces early cardiovascular events after non-cardioembolic ischemic stroke.
Zini et al. (2026) conducted an RCT in Non-cardioembolic ischaemic stroke. Tailored antiplatelet strategy guided by platelet aggregation testing vs. Usual care was evaluated on 3-month cumulative incidence of a composite of recurrent ischaemic stroke, myocardial infarction, or cardiovascular death. The TAILOR trial is a planned randomized study designed to evaluate whether a platelet function-guided antiplatelet strategy reduces 3-month cardiovascular events from an assumed 9% to 5%.